National Comprehensive Cancer Network

About NCCN

UPDATES: NCCN Guidelines® and NCCN Compendium®

NCCN Flash Update sent October 29, 2013

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer. These NCCN Guidelines® are currently available as Version 1.2014.

  • Treatment for cT2 disease (BL-4)
    • The follow-up and adjuvant treatment pathway was split between patients undergoing bladder preservation treatment and patients with extensive comorbidity or poor performance status.
  • Primary treatment for cT3 and cT4a disease (BL-5)
    • The radical cystectomy treatment option was revised: "...and strongly consider recommend neoadjuvant cisplatin-based combination chemotherapy (category 1)."
  • Principles of Chemotherapy Management (BL-G 2 of 3)
    • "Radiosensitizing chemotherapy regimens" heading was revised by adding "for bladder-preserving chemoradiation following a maximal TURBT" and for first-line chemotherapy, "cisplatin and paclitaxel" was added as a category 2B recommendation.
    • A new section was added titled: "Radiosensitizing chemotherapy given concurrently with conventionally fractionated radiation for palliation of metastases or for pelvic recurrence after cystectomy." The following treatment options were added:
      • Cisplatin
      • Taxane (docetaxel or paclitaxel) (category 2B)
      • 5-FU (category 2B)
      • 5-FU and mitomycin C (category 2B)
      • Capecitabine (category 3)
      • Low-dose gemcitabine (category 3)
  • Principles of Radiation Management (BL-H 2 of 2)
    • A new section related to the radiation management of "Carcinoma of the Urethra" was added.
  • New guidelines for the treatment of "Primary Carcinoma of the Urethra" were added. (PCU-1)

For the complete updated versions of the NCCN Guidelines, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.

To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.

Free NCCN Guidelines apps for iPad and Android tablets are now available! Visit NCCN.org/apps